-
Mashup Score: 15
Acquired resistance to molecularly targeted therapies remains a major challenge in the treatment of cancer. It has been hypothesized that drug-tolerant (or “persister”) cells without bona fide resistance mechanisms may survive initial …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Persistent Cancer Cells: The Deadly Survivors - PubMed - 1 month(s) ago
Persistent cancer cells are the discrete and usually undetected cells that survive cancer drug treatment and constitute a major cause of treatment failure. These cells are characterized by their slow proliferation, highly flexible energy consumption, adaptation to their microenvironment, and phenoty …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Persistent Cancer Cells: The Deadly Survivors shows how it is a challenge to study the complex ecosystem of persistent cancer cells in vivo. My lab is using innovative single-cell multi-omics to track these rare but lethal cells in #MCL. https://t.co/lwTyJ8k9cU https://t.co/lCS8q5IB6Q
-
-
Mashup Score: 49Frontiers | Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma - 1 month(s) ago
In Mantle Cell Lymphoma (MCL), the role of macrophages within the tumour microenvironment (TME) has recently gained attention due to their impact on prognosi…
Source: www.frontiersin.orgCategories: General Medicine News, Hem/OncsTweet-
The roles played by macrophages in mantle cell lymphoma, and plans to weaponize them as CAR-macrophages for its treatment, are reviewed by Nylund et al. from Uppsala Univ; https://t.co/WaZM8ZKWAM https://t.co/DWf4uheJiJ
-
-
Mashup Score: 11
Single-cell multi-omics technologies and methods characterize cell states and activities by simultaneously integrating various single-modality omics methods that profile the transcriptome, genome, epigenome, epitranscriptome, proteome, metabolome and …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
So much data, so little time! Great review: The technological landscape & applications of single-cell multi-omics. My lab is interested in #multi-omics to understand #MCL tumor heterogeneity & evolution of cell states, leading to resistance. https://t.co/Q5TfRaOneK https://t.co/P5gO0ezU6s
-
-
Mashup Score: 12Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity - PubMed - 2 month(s) ago
The emergence of immune escape is a significant roadblock to developing effective chimeric antigen receptor (CAR) T cell therapies against hematological malignancies, including acute myeloid leukemia (AML). Here, we demonstrate feasibility of targeting two antigens simultaneously by combining a GRP7 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Anti-#AML bispecific CAR-T with linked GRP78-specific peptide antigen recognition domain and CD123-specific scFv. CAR-T cells killed tumor cells with GRP78, CD123, or both (better with both); linker characteristics crucial. https://t.co/efWKJRS61E https://t.co/chLHKLc8GE
-
-
Mashup Score: 11An expanded universe of cancer targets - PubMed - 2 month(s) ago
The characterization of cancer genomes has provided insight into somatically altered genes across tumors, transformed our understanding of cancer biology, and enabled tailoring of therapeutic strategies. However, the function of most cancer alleles remains mysterious, and many cancer features transc …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Oldie but a goodie. 2021 Cancer Target Discovery & Development (#CTD2) review highlights an Expanded Universe of Cancer Targets. My laboratory works to uncover master regulators that control oncogenic cell states, plasticity, & resistance in #MCL. https://t.co/CRv9vfg153 https://t.co/YOMfy2qBH6
-
-
Mashup Score: 66
Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
Recently, our laboratory reported that pirtobrutinib & venetoclax combination overcomes resistance to targeted & chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma (#MCL), activating enrollment for a phase II clinical trial. https://t.co/XRAllbP76c https://t.co/w0SomiMpl3
-
-
Mashup Score: 0Jennifer Johnston (@jennifer.b.johnston) • Instagram photo - 9 month(s) ago
21 likes, 1 comments – jennifer.b.johnston on August 17, 2023: “Two years ago I was estatic that Dr. Wang answered my email from Alaska. I felt once I was accep…”
Source: www.instagram.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Jennifer, we are so proud of you! @jennifer.b.johnston https://t.co/DstNTmIS18
-
-
Mashup Score: 1Special Issue "Cutaneous Lymphomas" - PubMed - 1 year(s) ago
Cutaneous lymphomas comprise heterogeneous subtypes of hematological neoplasms that primarily manifest in the skin […].
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @Lymphoma_Papers: Special Issue "Cutaneous Lymphomas" #lymphoma #lymsm https://t.co/My1FpQEI4B
-
-
Mashup Score: 1Resilience Is About How You Recharge, Not How You Endure - 1 year(s) ago
After working hard for long hours and toughing it out, we at least expect success. However, more often than not, at the end of the day we are exhausted and still have a long list of tasks to complete. Why does this happen? According to the authors, working adults have a fundamental misunderstanding of what it means to be resilient. Yes, resilience involves working hard, but it also requires one…
Source: Harvard Business ReviewCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @DrAnasYounes: Resilience Is About How You Recharge, Not How You Endure https://t.co/QfJjG3GkqC
-
Cancers review from Harvard’s Cabanos and Hata about drug-tolerant persister cells and resistance. Would like to know more about factors that push drug-tolerant persister cells to make the leap into drug-tolerant expanded persister cells. https://t.co/qSKNUPBIiU https://t.co/enKeQXuJFL